Corcept医疗 2026年季度报告

FORM 10-Q_______________________________________________________ ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number:000-50679_______________________________________________________ CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) 101 Redwood Shores ParkwayRedwood City, CA 94065(Address of principal executive offices, including zip code)_______________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-Tduring the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Acceleratedfiler☐Smallerreportingcompany☐Emerginggrowthcompany☐ Large accelerated filer☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicateby check mark whether the registrant is a shell company(as defined in Rule 12b-2 of the ExchangeAct).Yes☐No☒ On July22, 2026, there were 108,098,397 shares of common stock outstanding at a par value of $0.001 per share. TABLE OF CONTENTS PART I. FINANCIAL INFORMATION3ITEM1. FINANCIAL STATEMENTS3CONDENSED CONSOLIDATED BALANCE SHEETS3CONDENSED CONSOLIDATED STATEMENTS OF INCOME4CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME5CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS6CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY7NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS9ITEM2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS18ITEM3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK25ITEM4. CONTROLS AND PROCEDURES26PART II. OTHER INFORMATION27ITEM1. LEGAL PROCEEDINGS27ITEM1A. RISK FACTORS28ITEM2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS46ITEM3. DEFAULTS UPON SENIOR SECURITIES46ITEM4. MINE SAFETY DISCLOSURES46ITEM5. OTHER INFORMATION47ITEM6. EXHIBITS48SIGNATURES49 CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF INCOME(Unaudited)(In thousands, except per share data) CORCEPT THERAPEUTICS INCORPORATED CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In thousands) CORCEPT THERAPEUTICS INCORPORATED NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Summary of Significant Accounting Policies Description of Business Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us,” and “our”) is a commercial-stagebiopharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic,metabolic and neurologic disorders by modulating the effects of the hormone cortisol.In 2012, the United States Food and DrugAdministration (“FDA”) approved Korlym(“mifepristone”) 300mg tablets, as a once-daily oral medication for the treatment ofhyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetesmellitus or glucose intolerance and have failed surgery or are not candidates for surgery. In June 2024, we made an authorized genericversion of Korlym available. In March 2026, the FDA approved Lifyorli(relacorilant) in combination with the chemotherapymedication nab-paclitaxel as a treatment for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritonealcancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. In April 2026,we began selling and distributing Lifyorli in the United States. We have discoveredand patented fivestructurally distinct series ofselective cortisol modulators, consisting of more than1,000compounds. We are developing compounds from these series as potentialtreatments for a broad